MRI for radiotherapy treatment planning of stage III NSCLC: an MRI optimization study in healthy volunteers and patients

MRI for radiotherapy treatment planning of stage III NSCLC: an MRI optimization study in healthy volunteers and patients - MRI optimization study in stage III NSCLC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44655

Enrollment

Registered

2014-01-31

Start date

2014-03-20

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer non-small cell lung cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy volunteers - *18 years - written informed consent;Patients: - patients with histopathologically or cytologically proven stage III NSCLC (excluding T4N0) referred to the department of Radiation Oncology - * 18 years - written informed consent - recent (* 3 months) GFR value available

Exclusion criteria

Exclusion criteria: Healthy volunteers: - volunteers who meet exclusion criteria for MRI following the protocol of the department of Radiology of the UMC Utrecht;Patients: - patients who meet exclusion criteria for MRI following the protocol of the department of Radiology of the UMC Utrecht - patients for whom lying still in a supine position for 45 minutes is physically too strenuous (e.g. due to orthopnea) - Glomerular Filtration Rate (GFR) of

Design outcomes

Primary

Measure	Time frame
* Healthy volunteers: Quality of the scans will be assessed by rating the motion artifacts and visibility of the lung and mediastinal parenchyma. * Patients with stage III NSCLC: Optimization of lung MRI for radiotherapy purposes (i.e. tumor delineation and motion characterization) defined by the quality of the images. Quality will be assessed by rating of the scans regarding the visibility of the primary tumor, lymph nodes and mediastinal parenchyma.	—

Measure

Time frame

* Healthy volunteers: Quality of the scans will be assessed by rating the motion artifacts and visibility of the lung and mediastinal parenchyma. * Patients with stage III NSCLC: Optimization of lung MRI for radiotherapy purposes (i.e. tumor delineation and motion characterization) defined by the quality of the images. Quality will be assessed by rating of the scans regarding the visibility of the primary tumor, lymph nodes and mediastinal parenchyma.

—

Secondary

Measure	Time frame
The results of this optimization study will be used for the power analysis of consecutive studies.	—

Countries

Netherlands

Outcome results